CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding
Open Access
- 1 February 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 26 (2), 66-73
- https://doi.org/10.1097/fpc.0000000000000186
Abstract
Objective The aim of this study was to assess whether the CYP2C9*2 and/or *3 variants might modify the risk for NSAID-related upper gastrointestinal bleeding (UGIB) in NSAID users. Patients and methods We conducted a multicenter, case–control study in which cases were patients aged more than 18 years with a diagnosis of UGIB, and controls were matched (1 : 3) by sex, age, date of admission, and hospital. Exposure was defined as the mean number of defined daily doses (DDDs) of NSAIDs metabolized by CYP2C9 in the week preceding the index date. Three DDD categories were defined (0, ≤0.5, and >0.5). Exposure was constructed taking both NSAID use and CYP2C9 polymorphisms into account. Patients of non-European origin were excluded from the analysis. Results A total of 577 cases and 1343 controls were finally included in the analysis: 103 cases and 89 controls consumed NSAIDs metabolized by CYP2C9, and 88 cases and 177 controls were CYP2C9*3 carriers. The adjusted odds ratios (aORs) of UGIB associated with the CYP2C9*2 and wild-type alleles proved to be similar [OR=8.79 (4.50–17.17) and 10.15 (2.92–35.35), respectively] and lower than those of the CYP2C9*3 allele [aOR=18.07 (6.34–51.53)] for consumers taking more than 0.5 DDDs of NSAIDs metabolized by CYP2C9. Grouping genotypes into carriers and noncarriers of the CYP2C9*3 variant resulted in aORs of 16.92 (4.96–57.59) for carriers and 9.72 (4.55–20.76) for noncarriers, where DDDs were greater than 0.5. Conclusion The presence of the CYP2C9*3 variant increases the risk for UGIB associated with NSAID for DDDs greater than 0.5. The presence of the CYP2C9*2 allele shows no such effect.Keywords
This publication has 40 references indexed in Scilit:
- Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income CountriesPLoS Medicine, 2013
- Genomics and Drug ResponseNew England Journal of Medicine, 2011
- Prevalence of CYP2C9 polymorphisms in the south of EuropeThe Pharmacogenomics Journal, 2009
- Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in VitroDrug Metabolism and Disposition, 2008
- CYP2C9 polymorphism in non‐steroidal anti‐inflammatory drugs‐induced gastropathyJournal of Digestive Diseases, 2008
- Exploiting Hardy-Weinberg Equilibrium for Efficient Screening of Single SNP Associations from Case-Control StudiesHuman Heredity, 2007
- Allele variants of the cytochrome P450 2C9 genotype in white subjects from the netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDsClinical Therapeutics, 2006
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Upper Gastrointestinal Bleeding Associated with the Use of NSAIDsDrug Safety, 2004
- Estimating the Dimension of a ModelThe Annals of Statistics, 1978